| Previous Close | 7.95 |
| Open | 7.88 |
| Bid | 7.65 x 1800 |
| Ask | 8.13 x 1400 |
| Day's Range | 7.76 - 8.06 |
| 52 Week Range | 3.54 - 43.40 |
| Volume | 2,351,833 |
| Avg. Volume | 4,161,139 |
| Market Cap | 255.053M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M™, in adults 65 years of age and older. “The FDA’s decision to grant Fast Track Designation for NanoFlu reflects the urgent unmet medical need for a more effective vaccine against influenza, particularly in the older adult population which often experiences serious and sometimes life-threatening complications, of the disease” said Stanley C. Erck, President and Chief Executive Officer of Novavax.
GAITHERSBURG, Md., Jan. 09, 2020 -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020Company to host conference call today at 4:30 p.m. ET.
GAITHERSBURG, Md., Oct. 31, 2019 -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged 65 and over. The trial, for which the first participants have been enrolled, will evaluate the immunogenicity and safety of NanoFlu with its proprietary Matrix-M™ adjuvant, compared to a U.S.-licensed quadrivalent influenza vaccine. Top-line clinical data from the randomized, observer-blinded, active-controlled trial is expected in the first quarter of 2020 and would support a subsequent U.S. biologics license application (BLA) and licensure of NanoFlu using the U.S. Food and Drug Administration’s (FDA) accelerated approval pathway.
GAITHERSBURG, Md., Sept. 19, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
GAITHERSBURG, Md., Sept. 06, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
Novavax, Inc. (NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the presentation of new data from the company’s Prepare™ trial, a global Phase 3 clinical trial of ResVax™, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.
GAITHERSBURG, Md., Aug. 08, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of.
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S. Food and Drug Administration (FDA) on its End-of Phase 2 questions and has reached agreement on its Phase 3 trial design for NanoFlu™, its adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for older adults aged 65 and over. Novavax plans to initiate the pivotal Phase 3 clinical trial of NanoFlu in the fall of 2019, with top-line clinical data expected in the first quarter of 2020.
Gaithersburg, Md., Aug. 01, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
GAITHERSBURG, Md., July 31, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and.
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will utilize the accelerated approval pathway for licensure for NanoFlu™, its nanoparticle seasonal influenza vaccine candidate. The U.S. Food and Drug Administration (FDA) acknowledged in a recent letter that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in the first quarter of 2020.
Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for $18 million in cashOver 100 manufacturing and quality employees to join.
Novavax, Inc. (NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical trial. The U.S. Food & Drug Administration (FDA) has recommended that Novavax conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease in infants born to mothers vaccinated with ResVax. Novavax has recently held meetings with several European national regulatory agencies to solicit input on the Prepare trial and possible pathways to licensure in Europe. The next step will be to seek formal scientific advice this fall from the European Medicines Authority (EMA), the agency responsible for licensing vaccines for the European Union.
GAITHERSBURG, Md., June 04, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial.
GAITHERSBURG, Md., May 10, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes.
Novavax, Inc. (NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of Incorporation (the Amended Certificate) to effect the reverse stock split at a Special Meeting of Stockholders held on May 8, 2019. The reverse stock split is intended to give Novavax greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.
GAITHERSBURG, Md., May 01, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and.
GAITHERSBURG, Md., April 25, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of.
NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Levi & Korsinsky announces it has commenced an investigation of Novavax, Inc. (NASDAQ: NVAX) concerning possible breaches of fiduciary duty. To obtain additional ...
GAITHERSBURG, Md., April 09, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn, M.D., President of Research and Development, will share data from its.
CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.
GAITHERSBURG, Md., March 18, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months.